An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.

Noel Clarke shares a recent update in his work focused on the PARP inhibitor, olaparib for patients with castration-resistant prostate cancer (CRPC) in combination with abiraterone.

Biographies:

Noel W Clarke, Professor of Urologic Oncology, Director of the Genitourinary Research Group, Manchester University, Consultant Urologist at Salford Royal Hospital and The Christie, Manchester

Charles J. Ryan, MD